New Patents Issued Across Multiple Geographies in US, Europe and Japan

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2017 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in inflammatory disease, neurological disease and renal failure in the United States, Europe and Japan. The plasma gelsolin portfolio now includes 26 issued patents and many pending applications.